articleThe LancetNov 15, 2017GREEN OA

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

JDJoshua D. LeeEVEdward V. NunesPNPatricia NovoKBKen BachrachGLGenie L. Bailey

New York University · Columbia University Irving Medical Center · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

695
total citations
FWCI
69.28
Percentile
100%
References
29
Citations per year

Authors

23

Topics & keywords

Topics
Keywords
  • Buprenorphine
  • Medicine
  • Naltrexone
  • Opioid use disorder
  • Opioid antagonist
  • (+)-Naloxone
  • Opioid
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding